Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

TNF-α inhibitors on par with novel biologics for resolution of dactylitis, enthesitis

12 Jan 2020

Tumour necrosis factor-α (TNF-α) inhibitors infliximab, golimumab and adalimumab are as effective as novel biologic agents ustekinumab, secukinumab and ixekizumab in the treatment of dactylitis and enthesitis, results of a systematic review and meta-analysis have shown.

The investigators performed a systematic literature search and a pooled meta-analysis of randomized controlled trials (RCTs) with TNF-α inhibitors, anti–interleukin (IL)-12/23 (ustekinumab) and anti–IL-17 (secukinumab, ixekizumab) using the random-effects model. They also assessed bias using the Cochrane risk-of-bias tool.

Eighteen RCTs including 6,981 patients were eligible for the pooled analysis. Both TNF-α inhibitors and novel biologic agents effectively resolved dactylitis at week 24 (pooled risk ratio [RR] vs placebo, 2.57, 95 percent confidence interval [CI], 1.36–4.84 and RR, 1.88, 95 percent CI, 1.33–2.65, respectively). TNF-α inhibitors (RR, 1.93, 95 percent CI, 1.33–2.79) and novel biologics (RR, 1.95, 95 percent CI, 1.60–2.38) were also effective in the resolution of enthesitis at week 24.

Both biologic categories showed overlapping ranges of American College of Rheumatology 20 responses (TNF-α inhibitors: RR, 2.23, 95 percent CI, 1.60–3.11; pooled IL-12/23 and -17: RR, 2.30, 95 percent CI, 1.94–2.72) and similar quality of life improvement scores, with mean Health Assessment Questionnaire–Disability Index score changes of –0.29 (95 percent CI, –0.39 to –0.19) and –0.26 (95 percent CI, –0.31 to –0.22), respectively.

“Biologic agents with different mechanisms of action showed efficacy in RCTs in the treatment of psoriatic arthritis,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.